17 April 2020 - TLV has conducted an additional analysis of the earlier evaluation of Kymriah (tisagenleclucel) in the treatment of patients with diffuse large cell B lymphoma, as Novartis has provided new data in the form of longer follow-up time from the clinical study.
Novartis has also made so-called indirect comparisons between Kymriah and Yescarta and produced data based on the commercial use of the two products.
The indirect comparisons are intended to show the comparable effect between Kymriah and Yescarta.